Evidence map›Paper›PMID 40514742›Full record

ArticleJournal of medical case reports2025

Anti-melanoma differentiation-associated gene 5 antibody associated rapidly progressive interstitial lung disease in a pediatric patient: a case report.

Thitima Sirimontakan, Natalia Escobar, Fiona Kritzinger, Elizaveta Limenis, Greta Mastrangelo, Briseida Mema, Haifa Mtaweh

Abstract readCase Reports
In one paragraph

Article in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Thitima SirimontakanCritical Care Medicine Department, The Hospital for Sick Children, Toronto, ON, Canada.
Natalia EscobarDepartment of Pediatrics, University of Toronto, Toronto, ON, Canada.
Fiona KritzingerDepartment of Pediatrics, University of Toronto, Toronto, ON, Canada.
Elizaveta LimenisDepartment of Pediatrics, University of Toronto, Toronto, ON, Canada.
Greta MastrangeloDepartment of Pediatrics, University of Toronto, Toronto, ON, Canada.
Briseida MemaCritical Care Medicine Department, The Hospital for Sick Children, Toronto, ON, Canada.
Haifa MtawehCritical Care Medicine Department, The Hospital for Sick Children, Toronto, ON, Canada. haifa.mtaweh@sickkids.ca.ORCID http://orcid.org/0000-0002-7562-549X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRapidly progressive interstitial lung disease presents as a severe complication of juvenile dermatomyositis, particularly when associated with anti-melanoma differentiation-associated gene 5. We report a pediatric case that underscores the necessity for clinicians to maintain a high index of suspicion for early identification and management. CASE PRESENTATION: A previously healthy 7-year-old White girl presented with a 6-week history of generalized weakness, fever, joint pain, and abdominal pain. Initial examination revealed hypoxia, tachypnea, and hepatosplenomegaly. Laboratory tests were marked by thrombocytopenia, lymphopenia, elevated liver enzymes, high ferritin, high triglyceride, elevated muscle enzymes, and increased soluble IL-2 receptor, suggesting macrophage activation syndrome that was and managed with dexamethasone 5 mg/kg/m

conclusionsThis case demonstrates the diagnostic and therapeutic challenges in patients with rapidly progressive interstitial lung disease in the context of anti-melanoma differentiation-associated gene 5 associated juvenile dermatomyositis, who may not present with overt muscle and cutaneous features of juvenile dermatomyositis and whose lung disease can progress very rapidly. A high index of suspicion among clinicians is critical, and expedited diagnostic serology may assist with earlier diagnosis and initiation of therapy. Extracorporeal membrane oxygenation can be utilized as a bridge to diagnosis in the setting of severe refractory hypoxemic respiratory failure. However, despite aggressive treatment, the prognosis remains challenging.

Indexed as

AutoantibodiesDermatomyositisInterferon-Induced Helicase, IFIH1Lung Diseases, InterstitialMacrophage Activation SyndromeChildDexamethasoneDisease ProgressionFemaleGlucocorticoidsHumansRespiration, ArtificialAutoantibodiesDexamethasoneGlucocorticoidsIFIH1 protein, humanInterferon-Induced Helicase, IFIH1Anti-MDA5 antibodyCase reportECMOExtracorporeal membrane oxygenationILDInterstitial lung disease in childrenJDMJuvenile dermatomyositisRapidly progressive interstitial lung disease

Identifiers

PMID40514742
PMCPMC12164089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.